Sankt Johann In Tirol

Researchers are conducting the Austrian Hypertrophic Cardiomyopathy HCM Registry, a prospective study enrolling patients from multiple outpatient clinics across Austria, including academic and non-academic centers. The registry aims to collect detailed clinical data on patients with HCM to facilitate innovative epidemiological analyses and improve standards of care by understanding gaps in evidence for this heart condition. Participants undergo a structured examination process that includes assessment of HCM symptoms, medical and family history, medication use, and specific red flags related to HCM. Clinical data collected include electrocardiograms, echocardiography, laboratory tests, and genetic testing. All information is entered into an electronic case report form to support multicenter analyses approved by a steering committee. During the study, patients will be followed over an average of 20 years with ongoing collection of data related to all-cause mortality and cardiovascular events. The registry supports cross-sectional and longitudinal analyses, aiming to harmonize clinical care for HCM patients in Austria. The total participation time depends on continued follow-up and data collection throughout the study duration.

This research aims to evaluate the safety and effectiveness of implants produced and distributed by Falcon Medical, specifically focusing on the PROMIS Stem used in primary total hip arthroplasty THA. The study includes patients undergoing primary THA with Falcon Medical implants to monitor their clinical performance and improvements over time. Participants will receive primary total hip arthroplasty using the PROMIS Stem implant from Falcon Medical. This observational study collects data prospectively in a standardized manner without additional interventions or comparator groups. The study evaluates outcomes related to the implants performance during and after surgery. Participants will be followed for up to 20 years to assess outcomes such as stem migration and patient-reported outcomes measured by the WOMAC questionnaire. Data on intra-operative and early post-operative complications, as well as any revisions, will be collected. This long-term monitoring helps researchers understand the implants safety and efficacy.

Researchers are evaluating the safety and performance of LatGYNious, a specially designed pelvic floor mesh implant, for treating female pelvic organ prolapse. This condition involves the descent of pelvic organs, and the study focuses on women with symptomatic prolapse who are candidates for surgical treatment. The goal is to gather clinical data to understand how well this device works and its safety profile. LatGYNious combines two types of polypropylene meshes an ultra-light monofilament mesh with a wide hexagonal pore structure for elasticity, and a reinforced mesh with a smaller pore size for strong fixation. The implant is used in laparoscopic lateral suspension surgery, either preserving the uterus or after hysterectomy. If the uterus is preserved, part of the mesh is removed. Participants will receive this mesh implant during their surgical procedure. Participants will be involved in follow-up assessments up to 12 months after surgery to measure objective success, subjective success, quality of life, and any complications from the operation. They are expected to cooperate with these follow-ups to help researchers evaluate the treatment outcomes and safety over time. The total study duration includes these monitoring periods after the surgery.